Trial Profile
Phase I Dose Escalation Study of Millennium 9708 in Combination With Induction and Consolidation Chemotherapy in Adults ≥ 60 Years With Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jan 2023
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Daunorubicin (Primary) ; Ixazomib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 13 Dec 2022 Results assessing the safety and efficacy of ixazomib with conventional chemotherapy in older patients with acute myeloid leukemia, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 22 Aug 2022 Status changed from recruiting to completed.
- 18 Jan 2021 Planned End Date changed from 1 Feb 2022 to 1 Jan 2024.